My main concern is this: once they get to full
deployment of alternative assets, this company will be very profitable, but also risky.
The Nominating Stockholder and DCM have had and continue to have periodic discussions with CuraGen regarding methods
of delivering additional value to the CuraGen stockholders, including the possible
alternative deployment of CuraGen's capital and possible utilization
of CuraGen's tax
assets.